Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting tags : Ongoing save search
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.14 -17.54% 58K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
MDNAF | $1.14 -17.54% 58K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
CRDF | $4.16 -0.24% -0.24% 340K
|
Health Services
|
| O: 0.85%
H: 5.73%
C: -4.55%
ongoing preclinical meeting study
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
Published: 2024-04-05 (Crawled : 21:00) - globenewswire.com
ELTX | $9.25 0.33% 0.32% 25K
|
| Email alert
Add to watchlist
plify-201 cell ongoing preclinical meeting eli-002 therapeutics response study
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
Published: 2024-04-02 (Crawled : 00:00) - biospace.com/
ZLAB | $15.66 3.57% 3.45% 430K
|
Health Technology
|
| O: -2.33%
H: 0.0%
C: 0.0%
ongoing global meeting key
PNM Resources Management to Meet with Investors 2024 ongoing earnings guidance to be affirmed during meetings
Published: 2024-03-04 (Crawled : 12:00) - prnewswire.com
PNM | $36.63 0.94% 0.0% 520K
|
Utilities
|
| O: -0.35%
H: 4.01%
C: 3.3%
management ongoing
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting
Published: 2023-12-11 (Crawled : 14:30) - globenewswire.com
BMEA | $10.76 -2.0% -2.04% 850K
|
Professional, Scientific, and T...
|
| O: -24.51%
H: 1.49%
C: -7.69%
alent-101 first disease ongoing bmf-219 meeting leukemia study
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
MOLN | $3.88 -3.54% 200
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
mp0533 first positive ongoing aml meeting trial molecular
TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition
Published: 2023-12-04 (Crawled : 21:00) - globenewswire.com
TCRX | News 3 d | $7.39 1.79% 1.76% 91K
|
Professional, Scientific, and T...
|
| O: -3.1%
H: 16.36%
C: 14.0%
tsc-100 tsc-101 ongoing meeting trial therapeutics results
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 1.02%
H: 4.5%
C: 3.38%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.04%
H: 1.92%
C: 1.89%
meeting hepatitis liver ongoing trials today
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 15:00) - biospace.com/
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 0.98%
H: 7.06%
C: 6.93%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.49%
H: 0.74%
C: -2.08%
meeting hepatitis liver ongoing trials
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
Published: 2023-11-03 (Crawled : 21:00) - globenewswire.com
ELTX | $9.25 0.33% 0.32% 25K
|
| Email alert
Add to watchlist
eli-002 cancer ongoing preclinical immunotherapy meeting therapeutics study
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
MOLN | $3.88 -3.54% 200
|
Professional, Scientific, and T...
|
| O: 0.72%
H: 9.74%
C: 9.74%
mp0317 tumors positive ongoing meeting trial molecular
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
Published: 2023-11-02 (Crawled : 15:30) - globenewswire.com
KRON | $0.9644 1.52% 1.49% 880K
|
Health Technology
|
| O: -0.18%
H: 13.95%
C: -4.93%
kb-0742 positive ongoing meeting study
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
Published: 2023-11-02 (Crawled : 13:00) - globenewswire.com
CNTA | News | $9.475 0.8% 0.79% 2.2M
|
Manufacturing
|
| O: -0.58%
H: 8.22%
C: 0.59%
year treatment ongoing pharmaceuticals meeting study
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
NTLA | $21.16 -1.72% -1.75% 860K
|
Health Technology
|
| O: 2.35%
H: 1.63%
C: 1.46%
ntla-2001 international ongoing meeting study
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
Published: 2023-11-02 (Crawled : 06:00) - globenewswire.com
MOLN | $3.88 -3.54% 200
|
Professional, Scientific, and T...
|
| O: 9.32%
H: 5.26%
C: 4.76%
mp0533 ongoing aml meeting trial molecular
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Published: 2023-11-01 (Crawled : 11:00) - globenewswire.com
MNPR | $0.63 -3.08% -3.17% 39K
|
Health Technology
|
| O: 53.88%
H: 8.81%
C: -16.88%
ongoing tumor meeting
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
Published: 2023-10-27 (Crawled : 12:00) - globenewswire.com
KRON | $0.9644 1.52% 1.49% 880K
|
Health Technology
|
| O: 1.14%
H: 2.25%
C: -5.09%
kb-0742 positive ongoing meeting study
Hollysys Provides Update on Ongoing Sale Process and Special Meeting Request; Discloses Offer from Management-Backed Buyer Group
Published: 2023-10-24 (Crawled : 13:30) - prnewswire.com
HOLI | $24.515 0.47% 0.47% 110K
|
Electronic Technology
|
| O: -0.32%
H: 8.77%
C: 5.56%
update group ongoing meeting
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.